Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16452917 | 1.00 | LMNA (0.71) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL7778087 | 1.00 | LMNA (0.71) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL9716670 | 1.00 | LMNA (0.71) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL5612699 | 0.98 | LMNA (0.73) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL10665563 | 0.98 | LMNA (0.73) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL9234559 | 0.98 | LMNA (0.73) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL9716658 | 0.92 | LMNA (0.82) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL31390220 | 0.92 | LMNA (0.82) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL9716661 | 0.92 | LMNA (0.82) | LMNATDP1PSMB5MEN1KMT2A | |
| SCHEMBL6562811 | 0.89 | CHRNB2 (0.59) | LMNATDP1PSMB5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-7314955-B2 | Form of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine | BIOCON LIMITED | 2008-01-01 | — | — | US | disclosed |
| WO-2007113650-A2 | A NOVEL AND IMPROVED PROCESS FRO THE PREPARATION OF NATEGLINIDE AND ITS POLYMORPH FORM-H | CADILA PHARMACEUTICALS LIMITED (IN) | 2007-10-11 | — | — | WO | disclosed |
| EP-1499586-A4 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | BIOCON LTD (IN) | 2006-01-18 | — | — | EP | disclosed |
| US-20050165108-A1 | reacting D-phenylalanine methylester HCl with trans-4-isopropylcyclohexane carboxylic acid in presence of propane phosphonic acid anhydride or LiOH Al2O3 in a halogenated hydrocarbon solvent such as dichloromethane or dichloroethane; type 2 diabetes mellitus | BIOCON LTD | 2005-07-28 | — | — | US | disclosed |
| EP-1435912-A4 | NOVEL STABLE CRYSTAL FORM OF N-TRANS-4-ISOPROPYLCYCLOHEXYL CARBONYL)-D-PHENYLALANINE AND PROCESS OF PREPARATION | ALEMBIC LTD (IN) | 2005-03-30 | — | — | EP | disclosed |
| EP-1499586-A1 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | Biocon Limited (IN) | 2005-01-26 | — | — | EP | disclosed |
| EP-1435912-A1 | NOVEL STABLE CRYSTAL FORM OF N-TRANS-4-ISOPROPYLCYCLOHEXYL CARBONYL)-D-PHENYLALANINE AND PROCESS OF PREPARATION | Alembic Limited (IN) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003093222-A1 | NOVEL FORM OF N-(TRANS-4-ISOPROPYLCYCLOHEXYLCARBONYL)-D-PHENYLALANINE | BIOCON LIMITED (IN) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003022251-A1 | NOVEL STABLE CRYSTAL FORM OF N-TRANS-4-ISOPROPYLCYCLOHEXYL CARBONYL)-D-PHENYLALANINE AND PROCESS OF PREPARATION | ALEMBIC LIMITED (IN) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | LMNA 4030/4885TDP1 4331/4885PSMB5 3900/4885 |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | LMNA 4030/4885TDP1 4331/4885PSMB5 3900/4885 |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | LMNA 4030/4885TDP1 4331/4885PSMB5 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.